|
1
|
Johnston IG, Paladino T, Gurd JW and Brown
IR: Molecular cloning of SC1: A putative brain extracellular matrix
glycoprotein showing partial similarity to osteonectin/BM40/SPARC.
Neuron. 4:165–176. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schraml P, Shipman R, Stulz P and Ludwig
CU: cDNA subtraction library construction using a magnet-assisted
subtraction technique (MAST). Trends Genet. 9:70–71. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Girard JP and Springer TA: Cloning from
purified high endothelial venule cells of hevin, a close relative
of the antiadhesive extracellular matrix protein SPARC. Immunity.
2:113–123. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Claeskens A, Ongenae N, Neefs JM, Cheyns
P, Kaijen P, Cools M and Kutoh E: Hevin is down-regulated in many
cancers and is a negative regulator of cell growth and
proliferation. Br J Cancer. 82:1123–1130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Socha MJ, Said N, Dai Y, Kwong J,
Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant
promoter methylation of SPARC in ovarian cancer. Neoplasia.
11:126–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tai IT, Dai M, Owen DA and Chen LB:
Genome-wide expression analysis of therapy-resistant tumors reveals
SPARC as a novel target for cancer therapy. J Clin Invest.
115:1492–1502. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lau CP, Poon RT, Cheung ST, Yu WC and Fan
ST: SPARC and Hevin expression correlate with tumour angiogenesis
in hepatocellular carcinoma. J Pathol. 210:459–468. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T and Pandey A: ONCOMINE: A cancer
microarray database and integrated data-mining platform. Neoplasia.
6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schlomm T, Luebke AM, Sültmann H,
Hellwinkel OJ, Sauer U, Poustka A, David KA, Chun FK, Haese A,
Graefen M, et al: Extraction and processing of high quality RNA
from impalpable and macroscopically invisible prostate cancer for
microarray gene expression analysis. Int J Oncol. 27:713–720.
2005.PubMed/NCBI
|
|
10
|
Isler SG, Ludwig CU, Chiquet-Ehrismann R
and Schenk S: Evidence for transcriptional repression of SPARC-like
1, a gene downregulated in human lung tumors. Int J Oncol.
25:1073–1079. 2004.PubMed/NCBI
|
|
11
|
Biade S, Marinucci M, Schick J, Roberts D,
Workman G, Sage EH, O'Dwyer PJ, Livolsi VA and Johnson SW: Gene
expression profiling of human ovarian tumours. Br J Cancer.
95:1092–1100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esposito I, Kayed H, Keleg S, Giese T,
Sage EH, Schirmacher P, Friess H and Kleeff J: Tumor-suppressor
function of SPARC-like protein 1/hevin in pancreatic cancer.
Neoplasia. 9:8–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu H, Zhang H, Ge W, Liu X, Loera S, Chu
P, Chen H, Peng J, Zhou L, Yu S, et al: Secreted protein acidic and
rich in cysteines-like 1 suppresses aggressiveness and predicts
better survival in colorectal cancers. Clin Cancer Res.
18:5438–5448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann
BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, et al:
SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol.
7:1019–1030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu Y, Chen Y, Ma J, Yu X, Yu G and Li Z:
SPARCL1 is a novel predictor of tumor recurrence and survival in
hilar cholangiocarcinoma. Tumour Biol. 37:4159–4167. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Turtoi A, Musmeci D, Naccarato AG, Scatena
C, Ortenzi V, Kiss R, Murtas D, Patsos G, Mazzucchelli G, De Pauw
E, et al: Sparc-like protein 1 is a new marker of human glioma
progression. J Proteome Res. 11:5011–5021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mintz MB, Sowers R, Brown KM, Hilmer SC,
Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et
al: An expression signature classifies chemotherapy-resistant
pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316.
2013.PubMed/NCBI
|
|
19
|
Hurley PJ, Marchionni L, Simons BW, Ross
AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z,
et al: Secreted protein, acidic and rich in cysteine-like 1
(SPARCL1) is down regulated in aggressive prostate cancers and is
prognostic for poor clinical outcome. Proc Natl Acad Sci USA.
109:14977–14982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hurley PJ, Hughes RM, Simons BW, Huang J,
Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, et
al: Androgen-Regulated SPARCL1 in the Tumor Microenvironment
Inhibits Metastatic Progression. Cancer Res. 75:4322–4334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang H, Widegren E, Wang DW and Sun XF:
SPARCL1: A potential molecule associated with tumor diagnosis,
progression and prognosis of colorectal cancer. Tumour Biol.
32:1225–1231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jakharia A, Borkakoty B and Singh S:
Expression of SPARC like protein 1 (SPARCL1), extracellular
matrix-associated protein is down regulated in gastric
adenocarcinoma. J Gastrointest Oncol. 7:278–283. 2016.PubMed/NCBI
|
|
23
|
Li P, Qian J, Yu G, Chen Y, Liu K, Li J
and Wang J: Down-regulated SPARCL1 is associated with clinical
significance in human gastric cancer. J Surg Oncol. 105:31–37.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cancer Genome Atlas Research Network:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato T, Arai E, Kohno T, Takahashi Y,
Miyata S, Tsuta K, Watanabe S, Soejima K, Betsuyaku T and Kanai Y:
Epigenetic clustering of lung adenocarcinomas based on DNA
methylation profiles in adjacent lung tissue: Its correlation with
smoking history and chronic obstructive pulmonary disease. Int J
Cancer. 135:319–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mencalha AL, Levinsphul A, Deterling LC,
Pizzatti L and Abdelhay E: SPARC-like1 mRNA is overexpressed in
human uterine leiomyoma. Mol Med Rep. 1:571–574. 2008.PubMed/NCBI
|
|
27
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and
Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are
prognosis-related in colorectal cancer. World J Gastroenterol.
17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative Analysis of Complex Cancer Genomics and Clinical
Profiles Using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hedditch EL, Gao B, Russell AJ, Lu Y,
Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et
al: ABCA transporter gene expression and poor outcome in epithelial
ovarian cancer. J Natl Cancer Inst. 106:pii: dju149. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
